SCHEMBL2921149

SCHEMBL2921149

Nc1ccc2nc(CN3CCCC3)ccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.48
DRD2 P14416 1/20 0.48
MCHR1 Q99705 3/20 0.47
HTR2C P28335 1/20 0.47
PLAU P00749 1/20 0.47
ACHE P22303 3/20 0.46
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 3/20 0.45
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
CASP6 P55212 1/20 0.45
MAPT P10636 3/20 0.43
FAAH O00519 2/20 0.42
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 2/20 0.39
MEN1 O00255 1/20 0.39
F2 P00734 1/20 0.39
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926351 0.98 ALDH1A1 (0.47) MAOADRD2MCHR1HTR2CPLAU
Hydrochloric Acid SCHEMBL27593291 0.88 ACHE (0.49) MAOADRD2MCHR1HTR2CACHE
SCHEMBL1352039 0.87 MAPT (0.55) MCHR1PLAUKDM4EMAPTSMN1; SMN2
SCHEMBL6229471 0.87 LMNA (0.50) MCHR1PLAUKDM4ELMNAPOLB
SCHEMBL10364825 0.84 PLAU (0.41) MAOADRD2MCHR1HTR2CPLAU
SCHEMBL6232343 0.82 MCHR1 (0.48) DRD2MCHR1KDM4EALDH1A1LMNA
SCHEMBL4507961 0.81 MCHR1 (0.47) MCHR1HTR2CKDM4EALDH1A1MAPT
SCHEMBL2326195 0.81 MAPT (0.50) MCHR1HTR2CKDM4EALDH1A1MAPT
SCHEMBL5764654 0.80 MCHR1 (0.49) DRD2MCHR1KDM4EALDH1A1FAAH
SCHEMBL6234696 0.79 MAPT (0.41) MCHR1PLAUKDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
WO-2004092181-A9 HETEROCYCLIC MCHR1 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2005-01-27 WO disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MAOA 195/4885DRD2 114/4885MCHR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.